Nurix therapeutics announces presentation of nx-1607 preclinical data at aacr

Cbl-b inhibitor nx-1607 mediates anti-tumor activity through both t cells and nk cells preclinical tumor models support clinical development of nx-1607 as monotherapy or in combination with pd-1 blockade
NRIX Ratings Summary
NRIX Quant Ranking